ASCEND final results: Acalabrutinib vs idelalisib plus rituximab or bendamustine plus rituximab in R/R CLL

Prof Paolo Ghia speaks to ecancer in an online interview for the virtual EHA 2020 meeting. He describes the background, design and latest results of the ASCEND trial, which examined the use of acalabrutinib versus idelalisib plus rituximab or bendamustine plus rituximab…

ASCEND final results: Acalabrutinib vs idelalisib plus rituximab or bendamustine plus rituximab in R/R CLL

Source

0
(0)

Prof Paolo Ghia speaks to ecancer in an online interview for the virtual EHA 2020 meeting.

He describes the background, design and latest results of the ASCEND trial, which examined the use of acalabrutinib versus idelalisib plus rituximab or bendamustine plus rituximab in relapsed/refractory chronic lymphocytic leukaemia (CLL).

Prof Ghia states that these results confirm the favourable efficacy and safety of acalabrutinib as seen in earlier analysis.

Sign up to ecancer for free to receive tailored email alerts for more videos like this.
ecancer.org/account/register.php

0 / 5. 0

Leave a Reply

Your email address will not be published. Required fields are marked *